ERX-315
Advanced/Metastatic Solid Tumors (e.g., breast, ovarian, pancreatic, endometrial, hepatocellular carcinoma)
Phase 1Active
Key Facts
Indication
Advanced/Metastatic Solid Tumors (e.g., breast, ovarian, pancreatic, endometrial, hepatocellular carcinoma)
Phase
Phase 1
Status
Active
Company
About EtiraRx
EtiraRx is a private, preclinical-stage biotech focused on oncology, specifically targeting the challenge of tumor heterogeneity in metastatic cancers. Its core technology involves small molecules that induce endoplasmic reticulum stress in cancer cells, a mechanism published in Nature Cancer. The company's lead asset, ERX-315, has entered a Phase 1 dose-escalation study in Australia, positioning EtiraRx in the competitive but high-need field of novel oncology therapeutics. With no approved products, the company is pre-revenue and reliant on investor funding to advance its pipeline.
View full company profile